Summary: Kasabach-Merritt phenomenon (KMP) is a rare consumptive coagulopathy characterized by profound thrombocytopenia and hypofibrinogenemia occurring in association with the vascular tumors kaposiform hemangioendothelioma (KHE) and tufted angioma (TA). Treatment remains challenging without consensus on the optimal medical management. The authors compiled expert opinions regarding management to establish treatment recommendations. Twenty-seven vascular anomalies centers in the United States and Canada were surveyed using 2 representative cases of KHE/TA with and without KMP. Overall response rate was 92% (25/27) with 88% completion (24/27). Most sites (23/25; 92%) do not have a standard of practice for management. The most frequent initial therapy for KHE + KMP was a combination of systemic corticosteroids and vincristine (VCR) (12/24 centers; 50%) followed by corticosteroids alone (29%). Second-line treatments were VCR (38%), rapamycin (21%), and propranolol (21%). Management of KHE/TA without KMP was variable; initial treatments included systemic corticosteroids (8/24; 33%) alone or with VCR (9/24; 38%), monitoring without medication (33%), VCR (8%), propranolol (8%), aspirin (4%), and rapamycin (4%). This survey highlights certain trends in the management of KMP-associated tumors, without standard protocols and consensus.
BACKGROUND
Kasabach-Merritt phenomenon (KMP) is a rare potentially life-threatening, consumptive coagulopathy associated with the vascular tumors: kaposiform hemangioendothelioma (KHE) and tufted angioma (TA). KMP was first described in 1940 by Kasabach and Merritt in a 2-month-old boy who presented with what was diagnosed as a capillary hemangioma with profound thrombocytopenia and hypofibrinogenemia. 1 These rare vascular tumors when associated with KMP typically arise in early infancy and are rapidly growing, large (>5 cm), locally invasive solitary lesions that most commonly manifest on the extremities, trunk, and face or neck. 2 Retroperitoneal and intrathoracic lesions are less common but are frequently associated with KMP. 3 The clinical course is characterized by severe thrombocytopenia, microangiopathic anemia, hypofibrinogenemia, and elevated fibrin split products in the presence of an underlying vascular tumor. 2, 4 The coagulopathy is believed to be triggered by sequestration of platelets and clotting factors within the vascular lesion, which may lead to a systemic disseminated intravascular coagulation. 5 These tumors can result in significant morbidity and mortality (up to 30%) including hemodynamic instability, local invasion, and compression of vital structures. 2, 3, [5] [6] [7] [8] The significant morbidity and mortality associated with KMP necessitates aggressive treatment, but the management of these tumors varies widely among different academic centers with expertise in vascular anomalies. Surgical removal may result in definitive treatment of KMP, but KHE and TA are often unresectable due to the large size and infiltrating nature. 2, [9] [10] [11] [12] Tumor embolization in combination with medical, surgical, or radiation therapy have been used with limited degree of success. 2,9-11 Medical therapies include systemic corticosteroids, vincristine (VCR), a-interferon (IFN), cyclophosphamide, rapamycin, and more recently, propranolol. 13, 14 The literature regarding the use of these agents is limited, and there are no prospective studies that examine the efficacy and toxicities associated with their use in the setting of KMP. Oftentimes multimodal therapy is required. 15, 16 
Expert Survey
The treatment for KMP and associated vascular tumors remains challenging without consensus on the optimal medical management of unresectable lesions. These tumors are uncommon, and therefore, there is a lack of controlled studies, which makes it difficult to directly compare treatment modalities. Furthermore, patients with KMP show wide variation in response to different therapeutic options. The aggressive treatment needed to control KMP and associated complications prompted the authors to compile expert opinions regarding disease management, in attempt to establish treatment recommendations. Surveys of experts have been successfully used as part of the process of developing treatment protocols for other rare pediatric disorders including localized scleroderma and juvenile dermatomyositis. 17, 18 These surveys use clinical vignettes followed by a series of questions to collect the expert's approach toward management. 17, 18 This survey was conducted in preparation for a consensus meeting, aim of which was to develop protocols for the management of these tumors.
MATERIALS AND METHODS
To gain insight into expert experience and to assess the initial management of tumors associated with KMP, we conducted a survey via surveymonkey.com. Institutional Review Board approval was obtained. Our survey was developed by pediatric hematologists and pediatric dermatologists with the goal of collecting management data from 27 selected vascular anomalies centers in the United States and Canada. (Appendix A, http://links.lww.com/ JPHO/A41). Two representative cases were presented: the first (case 1) was that of an infant with an unresectable kaposiform hemangioendothelioma affecting the lower extremity exhibiting Kasabach-Merritt phenomenon (KHE + KMP), and the second (case 2) described an infant with an unresectable tufted angioma located on the trunk without Kasabach-Merritt phenomenon (KHE/TA, no KMP) (Fig. 1) . Each participating site submitted 1 survey even if multiple specialists participated in the completion of the survey.
RESULTS
The overall response rate of our survey was 92% (25/ 27) with 88% of participants (24/27) completing the entire survey. The responding centers were geographically diverse within the United States and Canada. Eighty-eight percent of respondents (22/25) indicated that patients with tumors associated with KMP are managed in an interdisciplinary vascular anomalies clinic at their institution. A wide variety of specialists routinely participate in the care of patients with KHE/TA ( Table 1) . Eighty percent of the vascular anomalies groups indicated that they had cared for 5 or more patients with these tumors at their institutions within the last 10 years; 7 of those institutions reported taking care of 10 or more patients over this period. The response data reflects the experience obtained from treating over 150 patients over the prior 10 years. All but 2 sites (25/27; 92%) reported that they do not have a written standard of practice for management of tumors associated with KMP.
The first case presented to survey participants illustrated an example of a KHE exhibiting KMP. Thirty-six percent (9/25) of vascular anomalies centers reported they would perform tissue biopsy to confirm the diagnosis, whereas 64% of centers (16/25) would rely upon clinical findings and laboratory studies to establish the diagnosis.
Initial laboratory diagnostic studies including: Complete blood count with platelet count, coagulation studies (prothrombin time, partial thromboplastin time, fibrinogen, and D-dimer levels) with magnetic resonance imaging studies constituted an adequate evaluation at 20/25 sites (80%). Twelve percent (3/25) included a basic metabolic panel and liver function tests and 8% (2/25) stated that a peripheral smear would also be reviewed.
Centers were also asked to comment on the use of blood products including platelet transfusions for the management of children with thrombocytopenia associated with KMP. Figure 2 illustrates respondent use of platelet transfusions. Responses were more varied when participants were asked about the role of other blood products to assist in the medical management of KMP. The participants were asked to comment about the use of cryoprecipitate. Sixty percent (15/25) used cryoprecipitate when active bleeding occurred, whereas 48% (12/25) used it when surgical intervention was planned. Twenty-four percent of sites (6/25) used cryoprecipitate routinely, with 2 centers indicating that fibrinogen levels would be closely monitored (and ideally maintained above 100) during treatment. Eleven sites advocated for the adjuvant use of fresh frozen plasma (FFP) in patients with KMP. Sixteen percent (4/25) supported routine use of FFP, whereas 32% (8/25) use FFP when active bleeding occurs and 20% (5/25) use it when surgical intervention is planned. Finally, epsilon aminocaproic acid is used at 7/25 centers (28%); one center supported its use only when bleeding occurred, whereas another center used it only when all other interventions failed.
The most common initial medical therapy for KHE + KMP reported by survey participants was a combination of systemic corticosteroids and VCR (12/24 centers; 50%) followed by systemic steroids alone (7/24 centers; 29%). One center reported using systemic steroids in combination with propranolol (1/24; 4%). The remaining 4 centers utilized VCR alone at a dose of 0.05 mg/kg intravenous (IV) weekly (2/24; 8%), cyclophosphamide (1/ 24; 4%), or rapamycin (sirolimus) (1/24; 4%) ( Table 2) . One of the centers that reported using systemic steroids alone indicated that VCR would be started within several days of starting the systemic steroids. The most common steroid dose used was the equivalent of 2 mg/kg/d of oral prednisone, and the majority of sites stated that the decision to use oral versus IV corticosteroids would depend upon the patient and clinical situation. The reported dosing regimens for VCR ranged from 0.025 to 0.05 mg/kg IV weekly. Dosage range responses for the remaining medications include: (1) propranolol (20 mg/5 mL) 2-5 mg/kg/d divided bid to tid; (2) rapamycin 1 mg/m 2 /dose twice daily, and (3) cyclophosphamide (dose unlisted).
The length of treatment with systemic steroids was variable ranging between days to 1 year with a decision to continue dependent upon the tumor response. Responses in order of frequency included: 2 to 4 weeks of steroids followed by a taper (7/24 or 29%); repeated clinical assessment until KMP improves (5/24; 21%); 4 to 6 weeks of steroids followed by a taper (3/24,13%), and 6 to 12 weeks of steroids followed by a taper (3/24; 13%). The most common second-line treatments if the patient had not responded to initial treatments after 1 month were VCR (9/ 24; 38%), rapamycin (sirolimus) (5/24; 21%), and propranolol (5/24; 21%). Other second-line therapies included: cyclophosphamide (4/24), systemic steroids (3/24), embolization (2/24), and IFN (1/24).
Factors that the experts considered when making the decision to discontinue treatment included: improvement of the platelet count (22/24; 92%), a decrease in the size of the mass (19/24; 79%), resolution of functional impairment (15/ 24; 63%), and normalization of D-dimer levels (14/24; 58%).
Clinical Situation Percent of Sites Transfusing Platelets (25 sites)
Active bleeding 80% Surgical intervention planned 60% Platelet count <10,000 24% Depends on fibrinogen level 8% Determined "case-by-case" 8% The second patient vignette illustrated a case of a kaposiform hemangioendothelioma or TA without KMP. For this clinical scenario, the most common initial management recommendation was systemic corticosteroids alone (8/24; 33%) or in combination with VCR (1/24; 4%), clinical monitoring with periodic reassessment (8/24; 33%), VCR alone (2/24; 8%), propranolol (2/24; 8%), aspirin (1/ 24; 4%), and rapamycin (1/24; 4%). The most common second-line therapy was VCR (7/24; 29%) followed by systemic corticosteroids (3/24; 13%). Other second-line active treatments included: rapamycin (2/24; 8%), propranolol (2/23; 8%), and IFN (1/24; 4%) ( Table 2 ).
Active bleeding

DISCUSSION
The management of the tumors associated with KMP, KHE, and TA in infants and children remains controversial and problematic. Expert survey is a useful tool for assessing management of rare diseases and was particularly helpful in highlighting the need for further study and the importance of taking an interdisciplinary and multi-institutional approach to developing treatment protocols. This survey highlights that although there are certain trends in the management of KMP-associated tumors, standard protocols and consensus do not exist. Our survey results were used to provide a foundation for developing consensusdriven treatment protocols at an NIH-supported meeting of experts held in October 2011. The results of this conference including consensus driven management protocols are published separately. 19 Our survey found that the vast majority of patients with these tumors are managed in an interdisciplinary manner using the expertise of specialists with a broad array of experience. Medical management for tumors associated with KMP is variable, but certain trends were noted. Combination therapy consisting of systemic steroids and VCR was most commonly used to treat tumors causing KMP. Some centers explored the use of other agents such as rapamycin (sirolimus), propranolol, IFN, and cyclophosphamide. The use of propranolol for treating KMPassociated tumors has been described with variable response. 13, 14 The optimal doses of these medications has not been established. For rapamycin, the current dosing for the Phase II study (rapamycin for the treatment of complicated vascular anomalies) is 0.8 mg/m 2 /dose given twice daily. 20 Our study was not designed to document or compare the effectiveness of any of these therapies.
The majority of centers reported reserving the use of blood products including platelet transfusions and cryoprecipitate for situations in which active bleeding occurs or is anticipated. This survey also highlights the lack of established parameters for assessing response to therapy. The majority of respondents relied upon normalization of laboratory parameters and clinical response of the tumor on physical examination.
Management of KHE/TA not causing KMP was even more challenging and no clear trends were identified. Factors including the size and infiltrating nature of the lesion presented in the survey may not have been fully appreciated by respondents. The lack of consensus highlights the need for further investigation and the development of defined parameters to assess morbidity when these lesions are not associated with KMP.
Potential limitations of this study include the hypothetical nature of the cases used, although they were based upon real patient situations encountered by the authors. This may have made it difficult to convey some of the nuances of the clinical features upon which experts based their responses, particularly in case #2, in which the described patient did not have KMP associated with their tumor. The survey was sent to a select group of vascular anomalies centers/experts in the United States and Canada, and the responses may have been biased toward practices at major centers and practices that occurred over the previous 10 years. The latter might be important because of the emergence of newer therapeutic options, such as propranolol and rapamycin (sirolimus). 20, 21 Moreover, the management might not reflect that of wellestablished centers in other parts of the world. Likewise, given the uncommonness of these tumors, large time lapses may occur between cases, and because many specialists are often involved in any 1 patient's therapy, we acknowledge that there may be a potential for recall bias related to the respondents ability to remember the specifics of therapy for a particular patient. As noted previously, the results of this survey were used as a foundation for discussion among experts to develop consensus-driven treatment protocols for these rare tumors. The findings of this survey are particularly important because they document the existing treatment trends including those relating to the use of blood products that have not been previously well described. Ultimately, prospective multicenter controlled studies are required to determine treatment regimens for these potentially lifethreatening tumors.
